Changes in soluble PD-L1 levels in patients with advanced non-small cell lung cancer

Ta, Thang Ba; Pham, Nhung Thi Kim; Nguyen, Dung Tien; Tran, Tien Viet; Tran, Cuong Tan; Cong Luong, Thuc; Vu, Hoan Ngoc; Le, Hien Thi Dieu; Dao, Bang Ngoc

Changes in soluble PD-L1 levels in patients with advanced non-small cell lung cancer

Volume 15 (2024): Issue 1 (December 2024)

By:

Thang Ba Ta, Nhung Thi Kim Pham, Dung Tien Nguyen, Tien Viet Tran, Cuong Tan Tran, Thuc Cong Luong, Hoan Ngoc Vu, Hien Thi Dieu Le and Bang Ngoc Dao

Open Access

|Nov 2024

Figures & Tables

Distribution characteristics of mPD-L1 and sPD-L1.

mPD-L1 expression ratio in some clinical trials on NSCLC_

Clinical trials	Positive mPD-L1 expression ratio	PD-L1 antibody type
CheckMate 057^[18]	455/582 (78%)	28-8
CheckMate 017^[19]	225/272 (83%)	28-8
CheckMate 012^[20]	32/46 (70%)	28-8
CheckMate 227^[21]	1189/1739 (68%)	28-8
Keynote 189^[22]	63%	22C3
Keynote 001^[23]	60,8%	22C3
Keynote 010^[24]	1475/2222 (66%)	22C3
Keynote 021^[25]	56,8%	22C3
Keynote 042^[26]	1978/3019 (66%)	22C3
Keynote 024^[27]	500/1653 (30,2%)	22C3
POPLAR^[28]	109/287 (37,9%)	SP142
JAVELIN Lung 100^[29]	88/156 (56,4%)	73-10
JAVELIN Lung 200^[30]	527/792 (66%)	73-10

Values of sPD-L1 concentration according to clinical and paraclinical characteristics_

Feature	Subgroup	Median (IQR)	p**
Gender	Male (n = 59)	1.09 (0.5 – 2.56)	0.67
Gender	Female (n = 21)	0.93 (0.6 – 1.49)	0.67
Smoking	Yes (n = 38)	1.08 (0.56 – 2.43	0.965
Smoking	No (n = 42)	1.03 (0.59 – 2.28)	0.965
Staging	IIIB (n = 16)	1.06 (0.68 – 2.16)	0.764
Staging	IV (n = 64)	1.08 (0.52 – 2.36)	0.764
Age	≤ 65 (n = 40)	1.04 (0.55 – 2.49)	0.577
Age	> 65 (n = 40)	1.1 (0.67 – 2.27)	0.577
Tumor size	< 30 mm (n = 27)	1.49 (0.65 – 2.29)	0.981
Tumor size	≥ 30 mm (n = 53)	1.07 (0.56 – 2.28)	0.981
Phenotype	ADC (n = 58)	0.96 (0.59 – 2.25)	0.763
	SCC (n = 16)	1.17 (0.46 – 2.24)
	ASC (n = 6)	2.0 (0.57 – 3.59)
EGFR mutation	Positive (n = 24)	1.125 (0.69 – 2.2125)	0.187
EGFR mutation	Negative (n = 56)	2.56 (0.865 – 4.80)	0.187

Logistic regression model between increased sPD-L1 and mPD-L1 and clinical and paraclinical characteristics of NSCLC_

sPDL1 expression low – high	OR	SE	z	p	95% CI
Age	1.06	0.0317	1.85	0.065	0.996	1.121
Gender	0.34	0.2732	−1.34	0.179	0.072	1.635
BMI	0.86	0.1049	−1.27	0.204	0.673	1.088
Disease duration	1.003	0.0068	0.52	0.604	0.990	1.017
Clubbing	9.49	14.413	1.48	0.139	0.483	186.36
Bronchial Obstruction	0.06	0.0753	−2.19	0.029	0.004	0.7417
Tumor size	1.01	0.0152	0.77	0.442	0.982	1.042
Metastases	0.21	0.2167	−1.51	0.131	0.027	1.595
ADC	0.79	0.5333	−0.35	0.726	0.209	2.968
_cons	1.56	5.2885	0.13	0.896	0.002	1202.81
p = 0.031; R2 = 0.20

Characteristics of study subjects_

Feature	NSCLC (n₁ = 80)	Control (n₂ = 30)	p
General Characteristics
Age (X ± SD) (years)	65.58 ± 12.15	61.23 ± 15.84	0.096^*
Male	59 (73.75%)	14 (46.67%)	0.007^a
Female	21 (26.25%)	16 (53.33%)
Smoking	38 (47.5%)	8 (26.67%)	< 0.049^a
BMI	20,85 ± 2,41	21,1 ± 2,06	0.624^*
Clinical Features:
Fatigue	36 (45.0%)	0
Weight loss	32 (40.0%)	0
Fever	11 (13.75%)	0
Clubbing	7 (8.75%)	0
Peripheral Lymphadenopathy	15 (18.75%)	0
Cough	66 (82.5%)	0
Sputum	22 (27.5%)	0
Hemoptysis	9 (11.25%)	0
Chest pain	52 (65.0%)	0
Dyspnea	29 (36.25%)	0
Bronchial Obstruction	6 (7.5%)	NA
Consolidation syndrome	11 (13.92%)	NA
Pleural effusion	36 (45.0%)	NA
Mediastinal Syndrome	4 (5.0%)	NA
CT Chest Imaging Characteristics:
Nodules	27 (23.75%)	NA
Mass	53 (66.25%)	NA
Largest Tumor Size (X±SD) (mm)	47.73 ± 21.46	NA
Pleural effusion	38 (47.5%)	NA
Mediastinal lymph nodes	21 (26.25%)	NA
Atelectasis	15 (18.75%)	NA
Staging		NA
IIIB	16 (20.0%)	NA
IV	64 (80.0%)	NA
Pathology and Gene mutations:
ADC	58 (72.5%)	NA
SCC	16 (20.0%)	NA
ASC	6 (7.5%)	NA
EGFR mutation	24 (30.0%)	NA
sPD-L1 in PBMC:
Median (Min – Max)	1.08 (0.01 – 5.56)	0.42 (0.01 – 1.66)	< 0.001^**
mPD-L1 molecular expression:
Negative	31 (38.75%)	NA
Positive	49 (61.25%)	NA
Expression level
- Low (1 – 49%)	26 (32.5%)	NA
- High (≥ 50%)	23 (28.75)	NA
Median (min – max)	10 (0 – 50)	NA
X ± SD (%)	27.82 ± 33.61	NA

Relationship between mPD-L1 and sPD-L1 expression_

mPD-L1 expression		sPD-L1 Median (IQR)	p**
Not expressed (n = 31)		0.93 (0.48 – 2.06)	0.304
Expressed (n = 49)		1.09 (0.64 – 2.56)	0.304
Expression level	- Low (n = 26)	1.21 (0.65 – 2.7)	0.726
Expression level	- High (n = 23)	1.04 (0.49 – 2.56)	0.726

DOI: https://doi.org/10.2478/fco-2023-0036 | Journal eISSN: 1792-362X | Journal ISSN: 1792-345X

Journal RSS Feed

Language: English

Page range: 36 - 44

Submitted on: May 19, 2024

Accepted on: Aug 2, 2024

Published on: Nov 10, 2024

Published by: Helenic Society of Medical Oncology

In partnership with: Paradigm Publishing Services

Publication frequency: 2 times per year

Keywords:

soluble PD-L1 (sPD-L1),

membrane PD-L1 (mPD-L1),

non-small cell lung cancer (NSCLC)

Related subjects:

Medicine,

Clinical medicine,

Internal medicine,

Haematology, oncology

© 2024 Thang Ba Ta, Nhung Thi Kim Pham, Dung Tien Nguyen, Tien Viet Tran, Cuong Tan Tran, Thuc Cong Luong, Hoan Ngoc Vu, Hien Thi Dieu Le, Bang Ngoc Dao, published by Helenic Society of Medical Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous article Volume 15 (2024): Issue 1 (December 2024)Next article

Changes in soluble PD-L1 levels in patients with advanced non-small cell lung cancer

Figures & Tables

Figure 1:

Figure 2:

mPD-L1 expression ratio in some clinical trials on NSCLC_

Values of sPD-L1 concentration according to clinical and paraclinical characteristics_

Logistic regression model between increased sPD-L1 and mPD-L1 and clinical and paraclinical characteristics of NSCLC_

Characteristics of study subjects_

Relationship between mPD-L1 and sPD-L1 expression_

Paradigm

My account